AIM ImmunoTech Inc (AIM)

11:43 AM

AIM ImmunoTech advances Ampligen for avian influenza vaccine - MSN

11:43 AM

09:07 AM

AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist - TipRanks

09:07 AM

08:52 AM

AIM ImmunoTech announces a planned follow-up clinical study - GlobeNewswire

08:52 AM

08:51 AM

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks - The Manila Times

08:51 AM

08:50 AM

4X Immune Response: AIM's Ampligen Breakthrough with AstraZeneca's FluMist Against Bird Flu - StockTitan

08:50 AM

Feb 06, 2025

AIM ImmunoTech Inc (AIM) Has Recovered -14.29% From Its Low: Is This The Beginning Of A Trend? - Stocks Register

Feb 06, 2025

Feb 06, 2025

Stocks of AIM ImmunoTech Inc (AIM) are poised to climb above their peers - SETE News

Feb 06, 2025

Feb 05, 2025

Erasmus Medical Center Safety Committee Grants Approval to - GlobeNewswire

Feb 05, 2025

Feb 05, 2025

AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2 - TipRanks

Feb 05, 2025

Feb 05, 2025

Investing in AIM ImmunoTech Inc (AIM) might be a great opportunity, but the stock is a bit undervalued - US Post News

Feb 05, 2025

Feb 05, 2025

Breakthrough in Pancreatic Cancer Treatment: Clinical Trial Shows 15-Month Disease Stability - StockTitan

Feb 05, 2025

Feb 04, 2025

Daily Progress: AIM ImmunoTech Inc (AIM) Drop -8.07, Closing at 0.19 - The Dwinnex

Feb 04, 2025

Feb 04, 2025

AIM’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Feb 04, 2025

Feb 04, 2025

AIM ImmunoTech (NYSE:AIM) Stock Price Down 8.1% – What’s Next? - Defense World

Feb 04, 2025

Jan 28, 2025

AIM ImmunoTech Provides Business Update for the Third Quarter of 2019 - ACCESS Newswire

Jan 28, 2025

Jan 24, 2025

AIM ImmunoTech files to sell units, no amount given - MSN

Jan 24, 2025

Jan 23, 2025

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions - Marketscreener.com

Jan 23, 2025

Jan 23, 2025

AIM ImmunoTech Announces Publication of Final Clinical - GlobeNewswire

Jan 23, 2025

Jan 23, 2025

AIM ImmunoTech's Ampligen Shows Breakthrough Results in Long COVID Fatigue Treatment Trial - StockTitan

Jan 23, 2025

Jan 22, 2025

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS - GlobeNewswire

Jan 22, 2025

Jan 22, 2025

Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance

Jan 22, 2025

Jan 22, 2025

AIM ImmunoTech's Ampligen Shows Breakthrough Results for Long COVID and ME/CFS Treatment - StockTitan

Jan 22, 2025

Jan 20, 2025

AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN

Jan 20, 2025

Jan 20, 2025

Allegion Plc (ALLE-N) QuotePress Release - The Globe and Mail

Jan 20, 2025

Jan 15, 2025

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones - GlobeNewswire

Jan 15, 2025

Jan 15, 2025

AIM ImmunoTech Advances Ampligen Cancer Programs, Reports Strong Clinical Progress Across Pipeline - StockTitan

Jan 15, 2025

Jan 14, 2025

Mesoblast (NASDAQ:MESO) versus AIM ImmunoTech (NYSE:AIM) Head-To-Head Contrast - Defense World

Jan 14, 2025

Jan 11, 2025

Analyzing Mesoblast (NASDAQ:MESO) & AIM ImmunoTech (NYSE:AIM) - Defense World

Jan 11, 2025

Jan 09, 2025

Financial Survey: AIM ImmunoTech (NYSE:AIM) and INmune Bio (NASDAQ:INMB) - Defense World

Jan 09, 2025

Dec 22, 2024

AIM ImmunoTech shareholders elect new directors amid proxy battle By Investing.com - Investing.com South Africa

Dec 22, 2024

Dec 22, 2024

AIM ImmunoTech shareholders elect new directors amid proxy battle - Investing.com

Dec 22, 2024

Dec 21, 2024

Aim Immunotech director William Mitchell sells $883 in stock - Investing.com India

Dec 21, 2024

Dec 21, 2024

Aim Immunotech director William Mitchell sells $883 in stock By Investing.com - Investing.com Australia

Dec 21, 2024

Dec 20, 2024

Declaration of Voting Results by AIM ImmunoTech - Marketscreener.com

Dec 20, 2024

Dec 20, 2024

Ted Kellner low-key on joining pharma firm board he fought to join - The Business Journals

Dec 20, 2024

Dec 20, 2024

Aim Immunotech CEO Thomas K Equels acquires $4,681 in common stock - Investing.com Canada

Dec 20, 2024

Dec 18, 2024

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - The Manila Times

Dec 18, 2024

Dec 17, 2024

AIM ImmunoTech Announces Notification of Noncompliance with - GlobeNewswire

Dec 17, 2024

Dec 17, 2024

AIM ImmunoTech Faces NYSE American Listing Crisis After 5 Years of Losses - StockTitan

Dec 17, 2024

Dec 17, 2024

Pharma company proxy fight ends in mixed results for Ted Kellner - The Business Journals

Dec 17, 2024

Dec 17, 2024

AIM ImmunoTech Strengthens Board Leadership, Advances Cancer Drug Development Strategy - StockTitan

Dec 17, 2024

Dec 16, 2024

Ted Kellner's multimillion-dollar fight to unseat pharma firm's board - The Business Journals

Dec 16, 2024

Dec 16, 2024

AIM ImmunoTech Issues an Open Letter to Shareholders - Marketscreener.com

Dec 16, 2024

Dec 14, 2024

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board - GlobeNewswire Inc.

Dec 14, 2024

Dec 14, 2024

UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card - The Manila Times

Dec 14, 2024

Dec 13, 2024

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card - The Manila Times

Dec 13, 2024

Dec 13, 2024

AIM ImmunoTech gains Netherlands patent for post-Covid fatigue therapy - Yahoo Finance

Dec 13, 2024

Dec 13, 2024

AIM ImmunoTech secures patent for post-Covid fatigue therapy - Pharmaceutical Technology

Dec 13, 2024

Dec 12, 2024

AIM ImmunoTech Inc Provides Information to the Shareholders - Marketscreener.com

Dec 12, 2024